Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy to treat a form of liver disease. The FDA approved Wegovy for use in what’s called noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, in adults with moderate to advanced liver fibrosis.